Dr. Andres Hurtado-Lorenzo serves as the Senior Vice President of Translational Research & IBD Ventures at the Crohn's and Colitis Foundation. As the founder and head of the Foundation's venture philanthropy program, IBD Ventures, he drives innovation in inflammatory bowel disease by investing in biotech companies developing new products for IBD. In addition, Dr. Hurtado-Lorenzo oversees the Foundation's translational research portfolio, advancing patient-focused solutions in areas such as fibrosis, precision medicine, genetics, precision nutrition, environmental triggers, chronic pain, and biosensors. He also leads the IBD Therapeutics Incubator, currently dedicated to discovering antifibrotic drugs. A leader in translational science, Dr. Hurtado-Lorenzo, brings extensive experience directing multidisciplinary drug discovery and development teams within the biotech and pharmaceutical industry, including roles at Wyeth, Pfizer, and Proteostasis Therapeutics. His leadership has contributed to the development of clinical candidate drugs. Dr. Hurtado-Lorenzo earned his Ph.D. in Molecular Medicine & Gene Therapy from the University of Manchester in England, where he was a pioneer in gene therapy for neurodegenerative diseases. He completed postdoctoral research at Harvard Medical School, Massachusetts General Hospital, and Columbia University. His work is widely published in high-impact journals and books.